Pharma News

New molecule formed during omega-3 fatty acids metabolism in body may inhibit cancer

  • Posted on: 17 July 2018
  • By: PharmaTutor News

A class of molecules formed when the body metabolizes omega-3 fatty acids could inhibit cancer's growth and spread, University of Illinois researchers report in a new study in mice. The molecules, called endocannabinoids, are made naturally by the body and have similar properties to cannabinoids found in marijuana - but without the psychotropic effects.

Anti obesity drug derived from chilly seems effective

  • Posted on: 17 July 2018
  • By: PharmaTutor News

A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet, in new studies from the University of Wyoming School of Pharmacy. The drug, Metabocin, was designed to slowly release capsaicin throughout the day so it can exert its anti-obesity effect without producing inflammation or adverse side effects.

Aurobindo Pharma acquire Apotex business

  • Posted on: 17 July 2018
  • By: PharmaTutor News

Apotex, Canada’s largest generic pharmaceutical company, has signed an agreement to sell its commercial operations and certain supporting infrastructure for its generics business in five European countries to Aurobindo Pharma Limited. The sale will allow Apotex to focus its resources on the Americas where strong demand for its portfolio continues.

Fasting can be additional treatment to multiple sclerosis?

  • Posted on: 10 July 2018
  • By: PharmaTutor News

People with multiple sclerosis (MS) can find an abundance of conflicting advice suggesting that special diets - everything from avoiding processed foods to going low-carb - will ease their symptoms. But the evidence is scanty that dietary changes can improve fatigue or other MS symptoms.

New insight into Huntington's disease may open door to drug development : Researchers

  • Posted on: 10 July 2018
  • By: PharmaTutor News

McMaster University researchers have developed a new theory on Huntington's disease which is being welcomed for showing promise to open new avenues of drug development for the condition.  Huntington's disease is caused by a mutation in the gene that makes the protein called huntingtin.

Speeded-Up Drug Approval Process Will Boost Biologics Market

  • Posted on: 4 July 2018
  • By: PharmaTutor News

The US Federal Drug Administration is aiming to cut the time-to-market and the development costs for new drugs. This will help drive growth in the market for biologics, where over 1000 drugs are currently under development, to 9.6% year on year from its recent rate of 5.4%. Unlike small-molecule drugs that are manufactured through organic or inorganic chemical synthesis, biologics are manufactured by living cells. Biologics are more complex, fragile and difficult to manufacture than small molecules. They cost more to bring to market than the $2 billion average to develop a new drug, despite a trend to outsource development to contract research organizations.

CDSCO proposal to include all implantable medical devices & other high end equipment under the definition of 'drug'

  • Posted on: 29 June 2018
  • By: Shalini.Sharma

The Central government has moved forward with its plan to bring all implantable medical devices and other critical medical equipment under the purview of Section 3 (b) (iv) of the Drugs and Cosmetics (D&C) Act 1940 to ensure quality and reliability.

Pages